Data gathered: December 9
Alternative Data for Corvus Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| Patents | 23 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,912 | Sign up | Sign up | Sign up |
| Twitter Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 58 | Sign up | Sign up | Sign up |
| Linkedin Employees | 38 | Sign up | Sign up | Sign up |
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
| Price | $8.15 |
| Target Price | Sign up |
| Volume | 444,790 |
| Market Cap | $531M |
| Year Range | $1.36 - $9.56 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor ImmunityDecember 4 - Yahoo |
 |
OneDigital Investment Advisors LLC Trims Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)November 24 - ETF Daily News |
|
Head-To-Head Comparison: Corvus Pharmaceuticals (NASDAQ:CRVS) & Enanta Pharmaceuticals (NASDAQ:ENTA)November 19 - ETF Daily News |
|
Cantor Fitzgerald Analysts Lower Earnings Estimates for CRVSNovember 17 - ETF Daily News |
|
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic SclerosisNovember 13 - Yahoo |
 |
An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% UndervaluedNovember 13 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 2.1M | -2.1M | -40M | -7.2M | -0.600 |
| Q2 '24 | 0 | 1.8M | -1.8M | -4.3M | -5.9M | -0.040 |
| Q1 '24 | 0 | 2.2M | -2.2M | -5.7M | -6.2M | -0.120 |
| Q4 '23 | 250,000 | 1.7M | -3.1M | -6.7M | -5.6M | -0.140 |
| Q3 '23 | 0 | 1.6M | -2.5M | -6M | -5.5M | -0.120 |
Insider Transactions View All
| Jones William Benton filed to buy 19,357 shares at $0. May 7 '24 |
| Jones William Benton filed to buy 153,773 shares at $1.7. May 7 '24 |
| MILLER RICHARD A MD filed to buy 559,073 shares at $0. May 7 '24 |
| MILLER RICHARD A MD filed to buy 577,634 shares at $1.7. May 7 '24 |
| ORBIMED ADVISORS LLC filed to buy 1,397,684 shares at $0. May 8 '24 |
Similar companies
Read more about Corvus Pharmaceuticals (CRVS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Corvus Pharmaceuticals?
The Market Cap of Corvus Pharmaceuticals is $531M.
What is the current stock price of Corvus Pharmaceuticals?
Currently, the price of one share of Corvus Pharmaceuticals stock is $8.15.
How can I analyze the CRVS stock price chart for investment decisions?
The CRVS stock price chart above provides a comprehensive visual representation of Corvus Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Corvus Pharmaceuticals shares. Our platform offers an up-to-date CRVS stock price chart, along with technical data analysis and alternative data insights.
Does CRVS offer dividends to its shareholders?
As of our latest update, Corvus Pharmaceuticals (CRVS) does not offer dividends to its shareholders. Investors interested in Corvus Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Corvus Pharmaceuticals?
Some of the similar stocks of Corvus Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.